Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 11% to $68.50, ImmunityBio (NASDAQ:IBRX) shares are off 8% to $8.16, and Sarepta Therapeutics (NASDAQ:SRPT) stock has slid 8% to $18.84.
The moves are steep, but they land on top of extraordinary year-to-date gains. Moderna stock had climbed 160% year to date through Thursday’s close, and ImmunityBio shares were up 348% year to date heading into today. There’s no company-specific bad news attached to any of the three names.
The SPDR S&P Biotech ETF (NYSEARCA:XBI) is off 4% midday, framing this as a sector-wide flush rather than a single-name blowup. The equal-weighted sector proxy holds all three of today’s decliners among its constituents.
Profit-Taking After a Parabolic Run
The cleanest read on today’s selloff in Moderna, ImmunityBio, and Sarepta and other biotechnology stocks is profit-taking and sector rotation after a parabolic run. Recent news flow on all three names was actually bullish, and no headline catalyst has surfaced to explain the move.
ImmunityBio has ridden Russell 1000 inclusion hopes and Anktiva optimism to its triple-digit gain, with Q1 2026 revenue of $44.21 million up 168% year over year and ANKTIVA unit sales up 168% year over year. Sarepta Therapeutics stock, meanwhile, was just upgraded by Wolfe Research to Outperform with a $27 target, implying 34% upside from Thursday’s close.
Moderna’s own Q1 2026 print was strong: revenue of $389 million beat the consensus estimate by 65%, and management reaffirmed up to 10% revenue growth for the year. The near-term catalyst is the mRNA-1010 seasonal flu vaccine PDUFA date of August 5.
Big Pharma Barely Flinches
The rotation angle sharpens when you look outside biotech. Eli Lilly (NYSE:LLY) stock is down 3% midday, while Johnson & Johnson (NYSE:JNJ) shares are off by just 1%.
That gap tells the story. Money is coming out of high-beta, pre-profit biotech names and holding still in defensive large-cap pharma, where Eli Lilly stock is still up 10% year to date and Johnson & Johnson stock is up 24% year to date.
XBI Puts the Selloff in Perspective
The SPDR S&P Biotech ETF is the cleanest sector proxy since it holds Moderna, ImmunityBio, and Sarepta among its equal-weighted constituents. Even after today’s drop, XBI is still up 78% over the past 12 months.
Because the ETF is equal-weighted, its move reflects broad biotech weakness rather than one name driving the move. The fund isn’t leveraged, but it is a volatile sector vehicle, and today’s action is a reminder of how quickly biotech beta cuts both ways.
Moderna: Bull Case Meets Bear Case
The bull case for Moderna leans on the pipeline. The August PDUFA on the flu vaccine, brands including Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX, and a year-end cash target of $4.5 billion to $5 billion give management runway. Reddit retail sentiment sits at 72, classified as bullish, framing the run as a “savage comeback” comparable to post-dotcom recovery.
The bear case is the price action. Moderna stock is down 71% over five years, cash burn remains heavy after a $1.34 billion GAAP net loss, and consensus analyst targets sit well below the current price. Investors may want to size their positions modestly given the high-beta profile visible in today’s move.
What to Watch Next
The immediate tell is whether XBI stabilizes into the close or accelerates lower, which would signal the rotation has more room to run. Moderna’s August 5 PDUFA decision is the next hard-dated catalyst on the calendar for the primary name.
The takeaway: today’s slide in Moderna, ImmunityBio, and Sarepta looks like an unwind after a historic biotech rally rather than a fundamental rerating. Investors holding these names may want to reassess their position sizing given how quickly a sharp one-month gain in Moderna can compress into a double-digit down day.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks